- Home
- RGC vs BMRN Comparison
RGC vs BMRN Comparison
Compare RGC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | BMRN |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.5B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RGC | BMRN |
|---|---|---|
| Price | $27.81 | $54.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $88.22 |
| AVG Volume (30 Days) | 155.5K | ★ 1.5M |
| Earning Date | 10-31-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ N/A | $30.52 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $9.39 | $50.76 |
| 52 Week High | $950.00 | $66.28 |
Technical Indicators
Market Signals| Indicator | RGC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 44.46 |
| Support Level | $22.43 | $51.77 |
| Resistance Level | $28.31 | $56.21 |
| Average True Range (ATR) | 3.52 | 1.36 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 17.96 | 28.97 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.